Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia
Stefania Fiorcari, Rossana Maffei, Valentina Audrito, et al.
Oncotarget (2016) Vol. 7, Iss. 40, pp. 65968-65981
Open Access | Times Cited: 96

Showing 1-25 of 96 citing articles:

Role of Bruton’s tyrosine kinase in B cells and malignancies
Simar Pal Singh, Floris Dammeijer, Rudi W. Hendriks
Molecular Cancer (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 597
Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment
Michael Hallek
American Journal of Hematology (2019) Vol. 94, Iss. 11, pp. 1266-1287
Open Access | Times Cited: 442
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients
Steven P. Treon, Jorge J. Castillo, Alan P Skarbnik, et al.
Blood (2020) Vol. 135, Iss. 21, pp. 1912-1915
Open Access | Times Cited: 294
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure
Jordan Gauthier, Alexandre V. Hirayama, Janaki Purushe, et al.
Blood (2020) Vol. 135, Iss. 19, pp. 1650-1660
Open Access | Times Cited: 287
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
Michael Hallek, Othman Al‐Sawaf
American Journal of Hematology (2021) Vol. 96, Iss. 12, pp. 1679-1705
Open Access | Times Cited: 280
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment
Michael Hallek
American Journal of Hematology (2017) Vol. 92, Iss. 9, pp. 946-965
Open Access | Times Cited: 266
Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
H. Yesid Estupiñán, Anna Berglöf, Rula Zain, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 184
Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy
Michael Hallek
American Journal of Hematology (2025)
Open Access | Times Cited: 2
Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy
Jan A. Burger, Susan O’Brien
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 8, pp. 510-527
Closed Access | Times Cited: 121
Targeting tumour microenvironment by tyrosine kinase inhibitor
Hor‐Yue Tan, Ning Wang, Wing Lam, et al.
Molecular Cancer (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 97
Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
Bhawana George, Sayan Mullick Chowdhury, Amber Hart, et al.
Cancers (2020) Vol. 12, Iss. 5, pp. 1328-1328
Open Access | Times Cited: 90
The role of Bruton's tyrosine kinase in the immune system and disease
Charlotte McDonald, Charalampos Xanthopoulos, Efterpi Kostareli
Immunology (2021) Vol. 164, Iss. 4, pp. 722-736
Open Access | Times Cited: 86
Multifunctional Nanovaccine Sensitizes Breast Cancer to Immune Checkpoint Therapy
Carina Peres, Ana I. Matos, Bárbara Carreira, et al.
Advanced Functional Materials (2024) Vol. 34, Iss. 33
Open Access | Times Cited: 9
TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia
Kemal Catakovic, Franz Josef Gassner, Christoph Ratswohl, et al.
OncoImmunology (2017) Vol. 7, Iss. 1, pp. e1371399-e1371399
Open Access | Times Cited: 66
The Role of Tumor-Associated Macrophages in Hematologic Malignancies
Emanuele Cencini, Alberto Fabbri, Anna Sicuranza, et al.
Cancers (2021) Vol. 13, Iss. 14, pp. 3597-3597
Open Access | Times Cited: 44
Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies
Stefan F. H. Neys, Rudi W. Hendriks, Odilia B. J. Corneth
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 42
Bruton’s Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy
Antonio García‐Merino
Cells (2021) Vol. 10, Iss. 10, pp. 2560-2560
Open Access | Times Cited: 41
B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia
Vera K. Schmid, Elias Hobeika
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 7
Alteration of human macrophage phenotypes by the anti-fibrotic drug nintedanib
Nessrine Bellamri, Claudie Morzadec, Audrey Joannes, et al.
International Immunopharmacology (2019) Vol. 72, pp. 112-123
Open Access | Times Cited: 50
BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia
Stefania Fiorcari, Rossana Maffei, Daniela Vallerini, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 43
Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL
Gerardo Ferrer, Byeongho Jung, Pui Yan Chiu, et al.
Leukemia (2021) Vol. 35, Iss. 11, pp. 3163-3175
Open Access | Times Cited: 40
Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease
Stefan F. H. Neys, Jasper Rip, Rudi W. Hendriks, et al.
Drugs (2021) Vol. 81, Iss. 14, pp. 1605-1626
Open Access | Times Cited: 40
Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia
Isabelle G. Solman, Lisa K. Blum, Jan A. Burger, et al.
Leukemia Research (2021) Vol. 102, pp. 106520-106520
Open Access | Times Cited: 36
Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance
Moritz Fürstenau, Barbara Eichhorst
Cancers (2021) Vol. 13, Iss. 6, pp. 1336-1336
Open Access | Times Cited: 36
Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes
Sining Zhu, Samantha Gokhale, Jaeyong Jung, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 36
Page 1 - Next Page

Scroll to top